Form 4: Mesa Laboratories CFO John Sakys Reports Expiration of Unexercised Stock Options

Mesa Laboratories' Chief Financial Officer, John Sakys, filed a Form 4 disclosing the expiration of 4,087 unexercised non-qualified stock options on June 10, 2025.

Summary

• John Sakys, Chief Financial Officer of Mesa Laboratories Inc. (MLAB), filed a Form 4 with the U.S. Securities and Exchange Commission.
• The filing reports the expiration of 4,087 non-qualified stock options (NSOs) on June 10, 2025.
• These options had an exercise price of $203.54 per share.
• The NSOs were granted on June 10, 2019, and vested 1/4 on each anniversary date from June 10, 2020.
• Following this transaction, Mr. Sakys directly beneficially owns 19,706 derivative securities.
• The options expired unexercised, indicating they were likely out-of-the-money at the time of expiration.

Sentiment

Score: 4

Explanation: The expiration of unexercised stock options indicates that the stock price was likely below the exercise price, which is a negative outcome for the option holder. For the company, it's a neutral event in terms of operations, but it does imply the stock has not performed sufficiently to make the options valuable.

Negatives

• 4,087 non-qualified stock options held by CFO John Sakys expired unexercised on June 10, 2025.
• The options had an exercise price of $203.54, implying that the market price of Mesa Laboratories' common stock was likely below this value at the time of expiration, rendering the options out-of-the-money and without value to the holder.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The expiration of options means fewer shares will be issued, slightly reducing potential dilution, but the underlying reason (out-of-the-money options) might reflect on stock performance.
• Employees (specifically John Sakys): Loss of potential value from unexercised options.

Key Dates

Recommendation

Keywords

Mesa Laboratories, MLAB, SEC Form 4, Stock Options, Non-Qualified Stock Options, Insider Transaction, Beneficial Ownership, CFO, John Sakys, Equity Compensation